A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

NCT00367445 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-01-29

No results posted yet for this study

Summary

To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Inhaled Human Insulin (Exubera)

DRUG

Insulin Glargine (Lantus)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00367445 on ClinicalTrials.gov